Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer to Transform Mental Health Treatment
Tuesday, 10 September 2024, 04:30
Appointment Announcement
Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, announced the appointment of Mark Pollack, M.D., as its new Chief Medical Officer. Dr. Pollack brings a wealth of experience in clinical research and innovations in mental health.
Goals and Vision
Reunion's commitment is clear: to revolutionize the treatment of underserved mental health disorders. Under Dr. Pollack's leadership, the company aims to spearhead and explore next-generation therapies that address critical gaps in the mental health landscape.
- Advancement of next-generation mental health therapies.
- Focus on underserved populations in need of innovative treatments.
- Emphasis on clinical excellence and research breakthroughs.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.